[144] Centessa Pharmaceuticals plc American SEC Filing

Rhea-AI Filing Summary

Centessa Pharmaceuticals plc (ticker CNTA) has filed a Form 144, signaling an intended sale of restricted securities under SEC Rule 144.

• Security: Common shares listed on Nasdaq.
• Shares to be sold: 10,000.
• Aggregate market value: $128,650.
• Shares outstanding: 133,618,774 – the proposed sale represents roughly 0.0075% of the float.
• Approximate sale date: 20 June 2025.
• Broker: UBS Financial Services Inc., Weehawken, NJ.
• Source of shares: 5,000 acquired via stock-option exercise (20 Jun 2025) and 5,000 via RSU vesting (31 Mar 2024).

The filing is a routine notice that enables an affiliate or insider to sell a modest amount of previously restricted stock. The dollar value and percentage of outstanding shares are immaterial to Centessa’s capital structure, and no adverse information is disclosed. Investors may view the transaction as ordinary portfolio diversification rather than a signal of fundamental change.

Positive

• None.

Negative

• Insider selling: A company affiliate plans to sell 10,000 shares, which some investors may interpret as a mildly negative sentiment signal, albeit immaterial in size.

Insights

Securities Analyst

TL;DR Modest insider Rule 144 sale of 10,000 CNTA shares; negligible at <0.01% float, no strategic impact.

The Form 144 indicates that an affiliate intends to sell 10,000 common shares, worth about $0.13 million, through UBS on 20 June 2025. Given Centessa’s 133.6 million shares outstanding, the sale equates to roughly 0.0075% of the float – far below any threshold that could pressure the share price or signal meaningful insider sentiment. No other sales were reported in the prior three months, and the shares stem from standard equity-compensation events (option exercise and RSU vest). With no accompanying negative disclosure, I categorize the filing as routine and not impactful for valuation or governance considerations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	10000	128650.00	133618774	06/20/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/20/2025	Exercise of stock option	Issuer			5000	06/20/2025	Cash
Common	03/31/2024	RSU Vest	Issuer			5000	03/31/2024	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Centessa (CNTA) shares are being sold under this Form 144?

The filing covers the proposed sale of 10,000 common shares.

What is the dollar value of the planned CNTA share sale?

The aggregate market value stated is approximately $128,650.

When is the planned sale date for the CNTA shares?

The filer lists an approximate sale date of 20 June 2025.

What percentage of Centessa’s total shares does the sale represent?

With 133,618,774 shares outstanding, the 10,000-share sale is about 0.0075% of the float.

Where will the CNTA shares be sold and through which broker?

The shares are to be sold on the Nasdaq via UBS Financial Services Inc.